You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202271 - 202280 of 207712 results
  1. Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus

    SBC: CAPSULOMICS INC            Topic: 300

    Barrett’s esophagus (BE) is the strongest known risk factor for, and obligate precursor of, esophageal high- grade dysplasia (HGD) and adenocarcinoma (EAC). However, determining future neoplastic progression risk is quite challenging in BE patients: current risk estimation is based solely on highly variable, subjective, observer-dependent histopathologic diagnoses (i.e., non-dysplastic (ND), Low ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Validation and early development of a blood-based rapid diagnostic test for sepsis endotypes

    SBC: INFLAMMATIX, INC.            Topic: 300

    ABSTRACT Sepsis, a systemic inflammatory condition, occurs as a complication of infection and in severe cases may be associated with acute and life-threatening organ dysfunction. In the US alone, sepsis claims ~270,000 lives each year among ~1.7 million patients diagnosed annually, and globally, sepsis-related mortality is estimated to account for 20% of total deaths. Although improvements in the ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Validation and Evaluation of Remote, Interactive Teams of Autonomous Systems (VERITAS)

    SBC: APTIMA INC            Topic: OSD09T004

    different modes, while using different combinations of subsystems. This presents a challenge for the personnel validating the system during design and development; the number of combinations of environments, modes, and subsystems is exponential. They cannot all be tested, so an optimal subset of tests must be run. We propose to develop VERITAS: Validation and Evaluation of Remote, Interactive Tea ...

    STTR Phase I 2010 Department of DefenseNavy
  4. Validation and Experimentation Toolkit for Spatiotemporal Reasoning (VETS)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: N101076

    To maximize the operational value of robotic systems, warfighters must be able to specify high-level commands to direct their autonomous partner’s activities using multiple interaction methods that effectively convey spatiotemporal goals and constraints. The risks involved with unintended behaviors by autonomous robots due to dissonance in warfighter and spatiotemporal reasoning could be catastr ...

    SBIR Phase I 2010 Department of DefenseNavy
  5. Validation and humanization of a PET imaging agent that targets PD-L1.

    SBC: Agenus Inc.            Topic: 102

    DESCRIPTION provided by applicant Several strategies have recently shown convincing clinical efficacy by stimulating adaptive immunity for the treatment of cancer Immune checkpoint inhibitors CpIs for example reactivate a patientandapos s own T cells to eliminate tumors by blocking interactions that cause tumor infiltrating lymphocytes TILs to become exhausted CpIs have shown significan ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Validation and numerical testing of turbine augmentors combustion computational modeling

    SBC: FICS, LLC            Topic: N/A

    "This proposed Phase II modeling effort is designed to improve the accuracy of numerical predictions of military gas turbine augmentors through a coordinated program of physics-based modeling improvements within the selected, state-of-the-art ComputationalFluid Dynamics (CFD) flow solver (named FP-Augmentor), and a concurrent test program to provide essential validation data for key models. The ma ...

    SBIR Phase II 2002 Department of DefenseAir Force
  8. Validation and Numerical Testing of Turbine Augmentors Combustion Computational Modeling

    SBC: FICS, LLC            Topic: N/A

    Technical Abstract: The objective of this proposal is to demonstrate the feasibilityof integrating numerical testing with benchmark measurements for developing a validated accurate numerical code for turbine augmentor combustion modeling.1- Feasibility of using our FPVortex code, that has been used in similar applications with proven record, for additional simulations will be studied. The code wil ...

    SBIR Phase I 2001 Department of DefenseAir Force
  9. Validation and qualification of an ex vivo human cardiac tissue-based assay for t

    SBC: ANABIOS CORPORATION            Topic: NCATS

    DESCRIPTION (provided by applicant): Drug-induced cardiac toxicity and adverse events remains a major challenge for both industry as well as regulators. The current strategies for early identification of these potential liabilities in the drug discovery and development process involves a combination of in vitro and in vivo assays, followed by an extensive ECG-based cardiac repolarization study whi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Validation and qualification of an ex vivo human cardiac tissue based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds

    SBC: ANABIOS CORPORATION            Topic: NCATS

    PROJECT SUMMARY Drug induced cardiac toxicity and adverse events remain a major challenge for both industry as well as regulators The current strategies for early identification of these potential liabilities in the drug discovery and development process involves a combination of in vitro assays animal models and an extensive ECG based cardiac repolarization study which is conducted on human su ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government